激光:Lu-PSMA-617作为RCC的系统治疗方法的第二阶段试验
Shir Hazut Krauthammer1,2, Wanling Xie3, Nicole LaBrecque4
1Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; skrauthammer@mgb.org.
概括
这项研究研究了Lu-PSMA-617治疗晚期清细胞细胞癌 (ccRCC) 在标准治疗后进展的患者中. 它评估了安全性和有效性,旨在建立针对PSMA的放射性药物治疗作为一种新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 放射性药物疗法是一种放射性药物疗法.
- 细胞癌研究 细胞癌研究
背景情况:
- 清细胞细胞癌 (ccRCC) 是一种流行且具有挑战性的恶性瘤,尽管目前的治疗方法,但往往进展.
- 前列腺特异性膜抗原 (PSMA) 存在于ccRCC瘤新血管结构中,具有潜在的治疗点.
- 卢-PSMA-617是前列腺癌的成熟疗法,对其他PSMA阳性癌症有前途.
研究的目的:
- 为了评估Lu-PSMA-617的安全性和有效性,在患有晚期PSMA阳性ccRCC的患者中.
- 评估客观响应率 (ORR) 作为主要终点.
- 探索二次终点,包括安全性,无进展生存率 (PFS) 和整体生存率 (OS).
主要方法:
- 一个单中心,开放标签,单臂,第二阶段临床试验.
- 在标准治疗 (ICI和TKI) 后进展的晚期PSMA阳性ccRCC患者中招募24名患者.
- 每6周给予最多6个Lu-PSMA-617周期,采用两阶段的患者招募设计.
主要成果:
- 主要终点是根据RECIST 1.1标准的客观响应率 (ORR).
- 二级终点包括安全性评估,无进展生存率 (PFS) 和整体生存率 (OS).
- 探索性目标侧重于将成像生物标志物,无细胞DNA和基因组数据与结果相关联.
结论:
- 这项前性试验将确定Lu-PSMA-617对高级ccRCC的安全性和初步疗效.
- 结果可能支持开发针对耐火性ccRCC的PSMA向放射性药物治疗.
- 这种方法为有限选择的患者提供了潜在的新型治疗途径.
更多相关视频
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.6K
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10.4K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...